NCT04987203 2025-08-22
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
AVEO Pharmaceuticals, Inc.
Phase 3 Active not recruiting
Clinical Trials
13 trialsNCT03136627 2021-12-06
Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC
AVEO Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT01673386 2020-10-27
TAURUS
AVEO Pharmaceuticals, Inc.
Phase 2 Terminated
NCT01745367 2020-10-27
BATON-BC
AVEO Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00502307 2020-09-01
A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma
AVEO Pharmaceuticals, Inc.
Phase 2 Completed
NCT01369433 2020-09-01
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
AVEO Pharmaceuticals, Inc.
Phase NA Terminated
NCT00970411 2017-01-05
Study of KRN951 in Patients With Solid Tumors
Kyowa Kirin Co., Ltd.
Phase 1 Completed
NCT01478594 2015-07-08
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
AVEO Pharmaceuticals, Inc.
Phase 2 Completed
NCT01306630 2014-01-27
A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
AVEO Pharmaceuticals, Inc.
Phase 1 Completed
NCT00660153 2012-08-28
Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers
AVEO Pharmaceuticals, Inc.
Phase 1 Completed
NCT00826878 2012-06-28
An Open-Label Study of QD Oral Administration of Tivozanib (AV-951) in Subjects With Non-Small Cell Lung Cancer (NSCLC)
AVEO Pharmaceuticals, Inc.
Phase 1 Completed
NCT00563147 2011-10-04
A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma
AVEO Pharmaceuticals, Inc.
Phase 1 Completed
NCT01210846 2011-09-26
A Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid Tumors
AVEO Pharmaceuticals, Inc.
Phase 1 Completed